Pharmacologic characterization of CT-711, a novel dual inhibitor of ALK and c-Met

Anaplastic lymphoma kinase (ALK) is a validated molecular target for patients harboring ALK rearrangement, which triggers the development of ALK inhibitors. However, the activation of mesenchymal-epithelial transition factor (c-Met) has emerged as a common cause of acquired resistance induced by sel...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Am J Cancer Res
Glavni autori: Wang, Lei, Gao, Mingzhao, Tong, Mengya, Xie, Chengying, He, Ye, Fu, Li, Li, Yun, Fu, Haoyu, Lou, Liguang
Format: Artigo
Jezik:Inglês
Izdano: e-Century Publishing Corporation 2018
Teme:
Original Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6129499/
https://ncbi.nlm.nih.gov/pubmed/30210922
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items